Vaccine Scheduler

Greece: Recommended vaccinations

	General recommendation
	Recommendation for specific groups only
	Catch-up (e.g. if previous doses missed)
	Vaccination not funded by the National Health system
	Mandatory vaccination

	Birth	Months											Years
	Birth	2	3	4	5	6	10	12	15	18	19	23	2	3	4	5	6	7	9	10	11	12	13	15	18
Coronavirus disease (COVID-19)¹																									COVID-19⁷

tuberculosis	BCG⁸

rotavirus infection²		ROTA		ROTA		ROTA

diphtheria		D		D		D		D	D		D				D			d			d		d		d⁹
tetanus		TT		TT		TT		TT	TT		TT				TT			TT			TT		TT		TT⁹
pertussis		acP		acP		acP		acP	acp		acp				acP			acp			acp		acp		acp¹⁰
poliomyelitis		IPV		IPV		IPV					IPV				IPV			IPV							IPV⁹
Haemophilus influenzae type b infection		Hib		Hib		Hib		Hib	Hib		Hib						Hib
hepatitis B	HepB¹¹	HepB		HepB		HepB					HepB														HepB¹²

pneumococcal disease³		PCV15 or PCV20		PCV15 or PCV20				PCV15 or PCV20¹³								PCV20

meningococcal disease⁴		MenB		MenB			MenC¹⁴	MenB													MCV4		MCV4		MCV4/MenB

measles⁵								MEAS		MEAS			MEAS		MEAS
mumps								MUMPS		MUMPS			MUMPS		MUMPS
rubella								RUBE		RUBE			RUBE		RUBE

varicella								VAR		VAR			VAR		VAR¹⁵

human papillomavirus infection																			HPV9 (F/M)¹⁶					HPV9 (F/M)¹⁷

influenza													LAIV ¹⁸				IIV3

herpes zoster⁶																									ZOS¹⁹

hepatitis A													HepA					HepA

Version:

Footnotes:

https://emvolio.gov.gr/
2 doses of RV1 (month 2 and 4) OR 3 doses of RV5 (month 2, 4 and 6)
PPSV23 recommended from 2 years of age in at-risk groups
MenACWY is recommended to all adolescents aged 11-12 years. It is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 6 months of age are recommended 3 doses at ages 2, 4 and 12 months (MenACWY-TT vaccine); Infants starting vaccination between 7 and 24 months: 2 doses, 2nd dose to is administered at least 12 weeks after the first dose (MenACWY-TT vaccine); Children starting vaccination after 2 years of age: 2 doses with 8 weeks interval (MenACWY-CRM or MenACWY-TT vaccine); In children who remain at high risk, a booster dose is recommended 3-5 years after completion of their primary course. The MenB-4C is recommended to healthy infants in two doses at 2 and 4 months of age, with a booster dose at 12-15 months of age. The MenB-4C is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 5 months of age are recommended 4 doses at ages 2, 4, 6 and 12–15 months (MenB-4C); Infants and toddlers starting vaccination at 6 to 23 months of age: 2 doses with minimum 8 weeks interval and a booster dose at age 12–23 months (MenB-4C); Children starting vaccination at 2 to 10 years of age: 2 doses with minimum 8 weeks interval (MenB-4C); Children starting vaccination from the age of 11 years: 2 doses with minimum interval of 1 month (MenB-4C); Individuals aged 10 years and above can be vaccinated with MenB-fHbp with a 3-dose regimen at 0, 1–2, 6 months. More details available at: https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/ethniko-programma-emboliasmwn-epe-paidiwn-kai-efhbwn/13728-tropopoihsh-ethnikoy-programmatos-emboliasmwn-paidiwn-kai-efhbwn-2025-xronodiagramma-kai-systaseis
21 Sept. 2017: temporary recommendation for measles vaccination in Greece. First Dose at 12 months of age, Second dose 3 months later or 4 weeks after Dose 1 in specific groups
for detailled information refer to https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/alles-systaseis-ths-ethnikhs-epitrophs-emboliasmwn/11437-skeptiko-emboliasmoy-gia-ton-erphta-zwsthra-aprilios-2023
18-59y high risk groups, 60-74 1 dose, = 75y 2 doses , immunocompromised 2 doses (interval 6 months).
Vaccination is also recommended for infants and children up to the age of 5 years who belong to an increased risk groups and who have not been previously vaccinated
Booster dose 18- 25 y with Tdap or Tdap-IPV, followed by Td or Tdap every 10 y.
Booster dose 18- 25 y with Tdap or Tdap-IPV, followed by Td or Tdap every 10 y. A single dose of Tdap or Tdap-IPV vaccine should be administered in each pregnancy, preferably from 27 to 36 weeks of gestation, as well as to unvaccinated women who have recently given birth, regardless of the interval between previous Tdacp vaccination.
Babies born to a mother infected with hepatitis B (or with unknown status) will be offered a first vaccine dose at birth simultaneously with HB immunoglobulin.
Three doses, high risk groups
Only for premature babies, the recommended schedule consists of 3 primary doses + 1 booster dose (3+1), otherwise the recommended schedule is 2+1.
MenC: 1 dose at the age of 10 months
For unvaccinated individuals born after 1990. Two doses recommended to people belonging to specific occupational categories.
Catch-up vaccination up to 18 years for those who missed out on vaccination (HPV vaccine is fully reimbursed in boys and girls aged 15-18 until 31.12.2023). 2 doses scheme up to 15 years with 6 months interval between doses, thereafter 3 doses. for specific at-risk groups vaccination can be extended up to 26 years.
Catch-up vaccination up to 18 years for those who missed out on vaccination (HPV vaccine is fully reimbursed in boys and girls aged 15-18 until 31.12.2025). 2 doses scheme up to 18 years. for specific at-risk groups vaccination can be extended up to 26 years.
children aged 2-5 years
Two doses (RZV vaccine) in immunocompromised.

More information available at:
https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/

Last update : 10 February 2025